Starting Dose of Dapagliflozin
For glycemic control in type 2 diabetes, start with dapagliflozin 5 mg once daily, with the option to increase to 10 mg if additional glucose lowering is needed; for all other indications (heart failure, chronic kidney disease, or cardiovascular risk reduction), start directly with 10 mg once daily 1.
Dosing by Indication
The starting dose depends entirely on your treatment goal:
For Glycemic Control (Type 2 Diabetes)
- Start at 5 mg once daily in adults and pediatric patients ≥10 years old 1
- Can uptitrate to 10 mg once daily if additional glycemic control is needed 1
- This applies whether used as monotherapy or add-on therapy
- Important limitation: Not recommended for glycemic control if eGFR <45 mL/min/1.73 m² (ineffective due to mechanism of action) 1
For Cardiorenal Protection (Non-Glycemic Indications)
- Start at 10 mg once daily for 1:
- Reducing risk of eGFR decline, ESKD, CV death, and heart failure hospitalization in CKD patients
- Reducing CV death, heart failure hospitalization, and urgent heart failure visits in heart failure patients
- Reducing heart failure hospitalization in type 2 diabetes patients with established CVD or multiple CV risk factors
Renal Function Considerations
Before initiating therapy, assess renal function 1:
- eGFR ≥45 mL/min/1.73 m²: Use standard dosing as above
- eGFR 25-44 mL/min/1.73 m²:
- Can still use 10 mg for cardiorenal indications
- Do NOT use for glycemic control (ineffective)
- eGFR <25 mL/min/1.73 m²: Do not initiate therapy, but may continue 10 mg if already on treatment 1
Volume Status Assessment
Correct volume depletion before starting dapagliflozin 1. This is critical to avoid intravascular volume depletion, particularly in elderly patients or those on diuretics.
Evidence Supporting Dose Selection
The FDA labeling clearly distinguishes between glycemic and non-glycemic indications 1. While research suggests that doses higher than 10 mg might provide additional cardiorenal benefits 2, the current evidence base and regulatory approval support the 5-10 mg range for glycemic control and 10 mg for cardiorenal protection.
Studies demonstrate that 10 mg provides approximately 71% of maximum glycemic effect, 61% of hematocrit effect, and 91% of serum creatinine effect 2. The 2025 ADA guidelines recognize SGLT2 inhibitors like dapagliflozin as having cardiovascular and kidney benefits across multiple indications 3.
Common Pitfalls to Avoid
- Don't start at 10 mg for glycemic control alone - begin at 5 mg and assess response
- Don't use for glycemic control if eGFR <45 - it won't work effectively
- Don't forget volume assessment - particularly important in elderly or those on loop diuretics
- Don't continue through surgery - withhold at least 3 days before major procedures to reduce DKA risk 1